Inactive Instrument

PCAS Stock

PCA

FR0000053514

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

09/02/24	Orapi: takeover bid reopens on February 12
02/02/24	Orapi: 3.15 million shares tendered to the takeover bid
22/12/23	Orapi: takeover bid opens on December 27
18/12/23	PCAS: 200 ME capital increase
03/11/23	PCAS: OPAS to start this Friday
24/10/23	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
16/10/23	Progyny, Inc. : Want to have a baby?
07/09/23	PCAS: Seqens launches minority share offer
06/09/23	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/07/23	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
01/06/23	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
25/05/23	PCAS: sale of Canadian subsidiary confirmed
25/05/23	PCAS to Divest Canadian Arm to Japan's DIC	MT

24/10/23	PCAS: Net Sales as of September 30, 2023	GL
06/09/23	PCAS: RESULTS AS OF JUNE 30, 2023	GL
27/07/23	Pcas: Net sales as of June 30, 2023	GL
25/05/23	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
02/05/23	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

09/02/24	Orapi : l'OPA réouvre le 12 février
02/02/24	Orapi : 3,15 millions d'actions apportées à l'OPA
05/01/24	Progyny, Inc.: ¿Quieres tener un bebé?
22/12/23	Orapi : l'OPA démarre le 27 décembre
18/12/23	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	03/05/2025
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	01/03/1999

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	01/03/2014
Janine Cossy BRD	Director/Board Member	-	-

PCAS Stock

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news: PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	+4.28%	+0.07%	+52.75%	+138.78%	1,258B
JOHNSON & JOHNSON	+2.13%	+4.27%	+51.21%	+91.36%	679B
ABBVIE INC.	+0.68%	+1.54%	+33.83%	+112.47%	518B
ROCHE HOLDING AG	-0.39%	+2.15%	+43.21%	+68.70%	390B
MERCK & CO., INC.	+1.38%	+0.27%	+72.42%	+45.30%	367B
NOVARTIS AG	+0.33%	+1.69%	+30.84%	+59.46%	307B
ASTRAZENECA PLC	-0.57%	+1.45%	+6.35%	+38.35%	293B
AMGEN INC.	+1.04%	-0.05%	+45.29%	+76.18%	252B
GILEAD SCIENCES, INC.	+1.46%	-0.59%	+42.48%	+125.82%	210B
Average	+1.07%	+1.05%	+42.04%	+84.05%	475B
Weighted average by Cap.	+1.92%	+1.18%	+45.33%	+96.74%